New-onset diabetes and statins: Throw the bath water out, but, please, keep the baby!

Metabolism: Clinical and Experimental

Volumn 64, Issue 4, 2015, Pages 471-475

  Katsiki, Niki ^a   Rizzo, Manfredi ^b,c   Mikhailidis, Dimitri P ^d   Mantzoros, Christos S ^e  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF PALERMO   (Italy)

^c Euro Mediterranean Institute of Science and Technology   (Italy)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Metabolic syndrome; New onset diabetes; Primary and secondary prevention; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETOGENESIS; DOSE RESPONSE; DYSLIPIDEMIA; GERIATRIC PATIENT; GLUCOSE HOMEOSTASIS; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; INSULIN SENSITIVITY; KOREA; LIFESTYLE; MOLECULAR BIOLOGY; NEW ONSET DIABETES; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; TREATMENT DURATION; FEMALE; HYPERCHOLESTEROLEMIA; MALE;

DIABETES MELLITUS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE;

EID: 84923653355     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.11.001     Document Type: Editorial

References (56)

1. Y. Cho, E.Y. Choe, and Y.-h. Lee Risk of diabetes in patients treated with HM 1 G-CoA reductase inhibitors Metabolism 2014 [in press]
2. A.A. Carter, T. Gomes, X. Camacho, D.N. Juurlink, B.R. Shah, and M.M. Mamdani Risk of incident diabetes among patients treated with statins: population based study BMJ 346 2013 2610
3. E.P. Navarese, A. Buffon, F. Andreotti, M. Kozinski, N. Welton, and T. Fabiszak Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus Am J Cardiol 111 2013 1123 1130
4. D. Preiss, S.R. Seshasai, P. Welsh, S.A. Murphy, J.E. Ho, and D.D. Waters Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
5. C.R. Dormuth, K.B. Filion, J.M. Paterson, and Canadian Network for Observational Drug Effect Studies Investigators Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases BMJ 348 2014 3244
6. T. Ma, M.H. Chang, L. Tien, Y.S. Liou, and G.P. Jong The long-term effect of statins on the risk of new-onset diabetes mellitus in elderly Taiwanese patients with hypertension and dyslipidaemia: a retrospective longitudinal cohort study Drugs Aging 29 2012 45 51
7. M. Brault, J. Ray, Y.H. Gomez, C.S. Mantzoros, and S.S. Daskalopoulou Statin treatment and new-onset diabetes: a review of proposed mechanisms Metabolism 63 2014 735 745
8. M. Schachter Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update Fundam Clin Pharmacol 19 2005 117 125
9. N.L. Zaharan, D. Williams, and K. Bennett Statins and risk of treated incident diabetes in a primary care population Br J Clin Pharmacol 75 2013 1118 1124
10. G. Corrao, B. Ibrahim, F. Nicotra, D. Soranna, L. Merlino, and A.L. Catapano Statins and the risk of diabetes: evidence from a large population-based cohort study Diabetes Care 37 2014 2225 2232
11. R. Cai, Y. Yuan, Y. Zhou, W. Xia, P. Wang, and H. Sun Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis PLoS One 9 2014 e104922
12. D.D. Waters, J.E. Ho, D.A. DeMicco, A. Breazna, B.J. Arsenault, and C.C. Wun Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials J Am Coll Cardiol 57 2011 1535 1545
13. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, and A.J. de Craen Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
14. M. Ruscica, C. Macchi, B. Morlotti, C.R. Sirtori, and P. Magni Statin therapy and related risk of new-onset type 2 diabetes mellitus Eur J Intern Med 25 2014 401 406
15. K.L. Ong, P.J. Barter, and D.D. Waters Cardiovascular drugs that increase the risk of new-onset diabetes Am Heart J 167 2014 421 428
16. K.L. Ong, D.D. Waters, M. Messig, D.A. DeMicco, K.A. Rye, and P.J. Barter Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study) Am J Cardiol 113 2014 1593 1598
17. J. Skoumas, C. Liontou, C. Chrysohoou, C. Masoura, K. Aznaouridis, and C. Pitsavos Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia Atherosclerosis 237 2014 140 145
18. M. Banach, M. Malodobra-Mazur, A. Gluba, N. Katsiki, J. Rysz, and A. Dobrzyn Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance Curr Pharm Des 19 2013 4904 4912
19. D.I. Swerdlow, D. Preiss, K.B. Kuchenbaecker, M.V. Holmes, J.E. Engmann, and T. Shah HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials Lancet 2014 [Epub ahead of print]
20. Y. Kawai, R. Sato-Ishida, A. Motoyama, and K. Kajinami Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus Drug Des Devel Ther 5 2011 283 297
21. M.J. Chapman, A. Orsoni, P. Robillard, N. Hounslow, C.A. Sponseller, and P. Giral Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies Curr Med Res Opin 30 2014 775 784
22. K. Yanagi, T. Monden, S. Ikeda, M. Matsumura, and K. Kasai A crossover study ofrosuvastatin and pitavastatin in patients with type 2 diabetes Adv Ther 28 2011 160 171
23. T. Yamakawa, T. Takano, S. Tanaka, K. Kadonosono, and Y. Terauchi Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus J Atheroscler Thromb 15 2008 269 275
24. T. Mita, S. Nakayama, H. Abe, M. Gosho, H. Iida, and T. Hirose Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia J Diabetes Investig 4 2013 297 303
25. K. Yokote, H. Shimano, M. Urashima, and T. Teramoto Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis Expert Rev Cardiovasc Ther 9 2011 555 562
26. K. Yokote, Y. Saito, and CHIBA Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study) J Atheroscler Thromb 16 2009 297 298
27. J. Sasaki, Y. Ikeda, T. Kuribayashi, K. Kajiwara, S. Biro, and K. Yamamoto A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance Clin Ther 30 2008 1089 1101
28. Cholesterol Treatment Trialists' (CTT) Collaborators, B. Mihaylova, J. Emberson, L. Blackwell, A. Keech, J. Simes, E.H. Barnes Cholesterol Treatment Trialists' (CTT) Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
29. K.L. Wang, C.J. Liu, T.F. Chao, S.J. Chen, C.H. Wu, and C.M. Huang Risk of new-onset diabetes mellitus versus reduction in cardiovascular events with statin therapy Am J Cardiol 113 2014 631 636
30. H. Naci, J.J. Brugts, R. Fleurence, B. Tsoi, H. Toor, and A.E. Ades Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials Eur J Prev Cardiol 20 2013 641 657
31. G. Savarese, A.M. Gotto Jr., S. Paolillo, C. D'Amore, T. Losco, and F. Musella Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis J Am Coll Cardiol 62 2013 2090 2099
32. V.G. Athyros, N. Katsiki, K. Tziomalos, T.D. Gossios, E. Theocharidou, E. Gkaliagkousi GREACE Study Collaborative Group Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study Arch Med Sci 9 2013 418 426
33. K.K. Ray, S.R. Seshasai, S. Erqou, P. Sever, J.W. Jukema, and I. Ford Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants Arch Intern Med 170 2010 1024 1031
34. M. Petretta, P. Costanzo, P. Perrone-Filardi, and M. Chiariello Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis Int J Cardiol 138 2010 25 31
35. S. Mora, R.J. Glynn, J. Hsia, J.G. MacFadyen, J. Genest, and P.M. Ridker Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials Circulation 121 2010 1069 1077
36. K. Tziomalos, A.I. Kakafika, V.G. Athyros, A. Karagiannis, and D.P. Mikhailidis The role of statins for the primary and secondary prevention of coronary heart disease in women Curr Pharm Des 15 2009 1054 1062
37. M. Banach, and D.P. Mikhailidis Statin therapy and new-onset diabetes: an attempt at recommendations Exp Rev Endocrinol Metab 8 2013 213 216
38. M. Barylski, D. Nikolic, M. Banach, P.P. Toth, G. Montalto, and M. Rizzo Statins and new-onset diabetes Curr Pharm Des 20 2014 3657 3664
39. P.M. Ridker, A. Pradhan, J.G. MacFadyen, P. Libby, and R.J. Glynn Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 380 2012 565 571
40. K.L. Wang, C.J. Liu, T.F. Chao, C.M. Huang, C.H. Wu, and S.J. Chen Statins, risk of diabetes, and implications on outcomes in the general population J Am Coll Cardiol 60 2012 1231 1238
41. European Association for Cardiovascular Prevention & Rehabilitation, Z. Reiner, A.L. Catapano, and G. De Backer ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
42. T.J. Anderson, J. Grégoire, R.A. Hegele, P. Couture, G.B. Mancini, R. McPherson, and G.A. Francis 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 29 2013 151 167
43. K.C. Maki, P.M. Ridker, W.V. Brown, S.M. Grundy, and N. Sattar An assessment by the Statin Diabetes Safety Task Force: 2014 update J Clin Lipidol 8 2014 S17 S29
44. N.A. Sattar, H. Ginsberg, K. Ray, M.J. Chapman, M. Arca, and M. Averna The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice Atheroscler Suppl 15 2014 1 15
45. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, and R. Belder Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
46. E.P. Navarese, M. Kowalewski, F. Andreotti, M. van Wely, C. Camaro, and M. Kolodziejczak Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention Am J Cardiol 113 2014 1753 1764
47. N. Katsiki, V.G. Athyros, A. Karagiannis, and D.P. Mikhailidis The role of statins in the treatment of type 2 diabetes mellitus: an update Curr Pharm Des 20 2014 3665 3674
48. E.W. Gregg, Y. Li, J. Wang, N.R. Burrows, M.K. Ali, and D. Rolka Changes in diabetes-related complications in the United States, 1990-2010 N Engl J Med 370 2014 1514 1523
49. S.F. Nielsen, and B.G. Nordestgaard Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study Lancet Diabetes Endocrinol 2014 [pii: [Epub ahead of print]]
50. C.V. Rizos, and M.S. Elisaf Antihypertensive drugs and glucose metabolism World J Cardiol 6 2014 517 530
51. Y. Yang, R.B. Wei, Y. Xing, L. Tang, X.Y. Zheng, and Z.C. Wang A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients Metabolism 62 2013 1858 1866
52. L.M. Younk, and S.N. Davis Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes Expert Opin Drug Metab Toxicol 8 2012 515 525
53. E. Lioudaki, E.S. Ganotakis, and D.P. Mikhailidis Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years Curr Vasc Pharmacol 9 2011 62 66
54. M. Rizzo, G.A. Spinas, G.B. Rini, and K. Berneis Is diabetes the cost to pay for a greater cardiovascular prevention? Int J Cardiol 144 2010 309 310
55. V.G. Athyros, and D.P. Mikhailidis Pharmacotherapy: statins and new-onset diabetes mellitus - a matter for debate Nat Rev Endocrinol 8 2012 133 134
56. P. Verdecchia, G. Reboldi, F. Angeli, C. Borgioni, R. Gattobigio, and L. Filippucci Adverse prognostic significance of new diabetes in treated hypertensive subjects Hypertension 43 2004 963 969